

Mercè Brunet Serra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5819801/publications.pdf>

Version: 2024-02-01

49
papers

2,742
citations

279701

23
h-index

206029

48
g-index

50
all docs

50
docs citations

50
times ranked

3567
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring of Donor-Derived Cell-Free DNA by Short Tandem Repeats: Concentration of Total Cell-Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 257-268.	1.3	13
2	Evaluación de las concentraciones plasmáticas de voriconazol en práctica clínica. <i>Ars Pharmaceutica</i> , 2021, 62, 305-314.	0.1	0
3	Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients. <i>Frontiers in Immunology</i> , 2019, 10, 873.	2.2	21
4	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2017, 105, 497-505.	0.7	4
5	High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. <i>International Immunology</i> , 2016, 28, 55-64.	1.8	19
6	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20.	1.0	78
7	T-Cell Cytokines as Predictive Markers of the Risk of Allograft Rejection. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S21-S28.	1.0	14
8	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	1.0	102
9	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 170-189.	1.0	95
10	High proportion of CD95+ and CD38+ in cultured CD8+ T cells predicts acute rejection and infection, respectively, in kidney recipients. <i>Transplant Immunology</i> , 2016, 34, 33-41.	0.6	12
11	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1125-1127.	1.3	7
12	High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. <i>Immunobiology</i> , 2016, 221, 595-603.	0.8	12
13	Flow Cytometry as Platform for Biomarker Discovery and Clinical Validation. <i>Biomarkers in Disease</i> , 2015, , 141-164.	0.0	1
14	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. <i>Kidney International</i> , 2014, 85, 1434-1443.	2.6	38
15	High Proportion of Pretransplantation Activated Regulatory T cells (CD4+CD25highCD62L+CD45RO+) Predicts Acute Rejection in Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 1213-1218.	0.5	35
16	Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> : A Multicenter Clinical Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1105-1112.	2.9	67
17	Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. <i>Clinical Biochemistry</i> , 2014, 47, 223-227.	0.8	21
18	Donor-recipient genetic diversity: the role of pharmacogenomics in kidney transplantation. <i>Pharmacogenomics</i> , 2013, 14, 1369-1372.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 552-556.	1.0	4
20	Risk Factors for a Low Linezolid Trough Plasma Concentration in Acute Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1913-1917.	1.4	53
21	Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1146-1154.	1.0	23
22	Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012, 30, 86-92.	0.3	9
23	Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 548-550.	1.5	38
24	Determinación de linezolid en plasma mediante cromatografía líquida de alta resolución para la monitorización terapéutica en pacientes. <i>Revista Del Laboratorio Clínico</i> , 2011, 4, 207-213.	0.1	0
25	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011, 25, 47-57.	1.2	116
26	Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3784-3793.	0.4	37
27	Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 772-777.	1.0	15
28	Individually Tailored Immunosuppression: Is There a Role for Biomarkers?. <i>Clinical Chemistry</i> , 2011, 57, 376-381.	1.5	3
29	Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial. <i>Transplantation</i> , 2010, 89, 994-1000.	0.5	42
30	Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. <i>Clinical Immunology</i> , 2010, 137, 337-346.	1.4	43
31	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2269-2276.	0.4	81
32	Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients. <i>Transplantation Reviews</i> , 2009, 23, 120-128.	1.2	15
33	Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 394, 1687-1696.	1.9	25
34	Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of flow electrophoresis and nanoflow LC-MS/MS. <i>Proteomics</i> , 2009, 9, 4991-4996.	1.3	44
35	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	1.0	398
36	Is the Intracellular ATP Concentration of CD4+ T-Cells a Predictive Biomarker of Immune Status in Stable Transplant Recipients?. <i>Transplantation</i> , 2009, 88, S78-S84.	0.5	31

#	ARTICLE	IF	CITATIONS
37	Effects of Cyclosporine, Tacrolimus and Sirolimus on Vascular Changes Related to Immune Response. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 416-422.	0.3	21
38	Improved Renal Function, With Similar Proteinuria, After Two Years of Early Tacrolimus Withdrawal From a Regimen of Sirolimus Plus Tacrolimus. <i>Transplantation</i> , 2008, 86, 620-622.	0.5	15
39	Mammalian Target of Rapamycin Inhibition Halts the Progression of Proteinuria in a Rat Model of Reduced Renal Mass. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2653-2660.	3.0	52
40	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007, 46, 474-481.	1.8	864
41	Sequential Determination of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients Treated with Mycophenolate Mofetil. <i>Transplantation</i> , 2006, 81, 541-546.	0.5	55
42	Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir. <i>Clinical Pharmacokinetics</i> , 2005, 44, 525-538.	1.6	16
43	Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 823-830.	0.9	71
44	Low-Dose Cyclosporine with Mycophenolate Mofetil Induces Similar Calcineurin Activity and Cytokine Inhibition as does Standard-Dose Cyclosporine in Stable Renal Allografts. <i>Transplantation</i> , 2004, 78, 1400-1403.	0.5	30
45	Pharmacodynamic Approach to Immunosuppressive Therapies Using Calcineurin Inhibitors and Mycophenolate Mofetil. <i>Clinical Chemistry</i> , 2003, 49, 1891-1899.	1.5	49
46	Therapeutic Drug Monitoring of Tacrolimus in Liver Transplantation, Phase III FK506 Multicenter Spanish Study Group: A Two-Year Follow-Up. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 602-606.	1.0	10
47	Multicenter Comparison of First- and Second-Generation IMx Tacrolimus Microparticle Enzyme Immunoassays in Liver and Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 676-679.	1.0	10
48	Effects of Long-Term Antiepileptic Therapy on the Catabolism of Testosterone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1995, 76, 371-375.	0.0	15
49	Positive versus negative symptoms in schizophrenia: Response to haloperidol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994, 18, 155-164.	2.5	13